NDC 81033-124-06 - Gabapentin
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 81033-124
- Requested NDC
- 81033-124-06
- Package NDCs from labels
- 81033-124-06, 81033-124-44
- Manufacturer
- Kesin Pharma Corporation
- Effective date
- 2025-09-19
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Gabapentin - Kesin Pharma Corporation | Kesin Pharma Corporation | 2025-09-19 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 81033-124-06 | Gabapentin | 6 mL in 1 CUP, UNIT-DOSE | SOLUTION | 6 | 1 | |
| 81033-124-44 | Gabapentin | 40 in 1 CARTON | SOLUTION | 40 | 1 |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 81033-124-06 | ML - Milliliter | 81033-124 | dac763c1-c481-43a1-86d4-7d259050a2c0 | 1 | 2025-10-14 |
| 81033-124-44 | ML - Milliliter | 81033-124 | 55a1fe8c-d9ba-4f1c-9663-d8638e8de22d | 1 | 2025-10-14 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Gabapentin | GABAPENTIN | ScieGen Pharmaceuticals, Inc. | 5ab9c18b-9568-4dcb-90b0-252aef8f8dc2 | 2026-02-20 | Warnings, Adverse reactions | 6CW7F3G59X |
| GABAPENTIN | GABAPENTIN | PD-Rx Pharmaceuticals, Inc. | 9814b76c-87c6-4746-b712-3269352a901b | 2026-02-16 | Warnings, Adverse reactions | 6CW7F3G59X |
| WowDay Hemorrhoid and Fissure Cream | HEMORRHOID AND FISSURE CREAM | WowDay LLC | 47ba86ad-240a-e733-e063-6394a90a24e3 | 2026-02-12 | Warnings | PDC6A3C0OX |
| GABAPENTIN | GABAPENTIN | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | d8daa30f-1cb3-46aa-9b68-d9aa5b0a2105 | 2026-02-12 | Warnings, Adverse reactions | 6CW7F3G59X |
| Viva Hydration Boost | GLYCERIN | Nomax Inc | 174193b2-65eb-b5fd-e063-6394a90a9cd0 | 2026-02-10 | Warnings | PDC6A3C0OX |
| Gabapentin | GABAPENTIN | A-S Medication Solutions | c979f80b-d4b1-40f7-b878-b216db5f325d | 2026-02-10 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | A-S Medication Solutions | b88b0cbc-c883-4d17-8f46-0e5bddc57835 | 2026-02-10 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | A-S Medication Solutions | 3dbd447f-4791-4c62-86b4-6f7928862785 | 2026-02-10 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | A-S Medication Solutions | 081fd1de-acaa-4685-a053-4959d77b17e9 | 2026-02-10 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | A-S Medication Solutions | 0e1d17d5-d39c-4144-aac0-7c0d3bc9ec0d | 2026-02-09 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | A-S Medication Solutions | 2343e3a1-82d0-4c70-a086-a01a0ce81ef3 | 2026-02-09 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | A-S Medication Solutions | 67330eef-c976-4862-b1ae-20f30f43df76 | 2026-02-09 | Warnings, Adverse reactions | 6CW7F3G59X |
| GABAPENTIN | GABAPENTIN | Bryant Ranch Prepack | 2e331641-ec26-4d76-b16b-a9863c767afe | 2026-02-06 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Bryant Ranch Prepack | cc1998a7-7004-4688-8b5b-525041851d1d | 2026-02-05 | Warnings, Adverse reactions | 6CW7F3G59X |
| Optase | GLYCERIN | Scope Health Inc | 376e0289-28e9-e87f-e063-6294a90a3b04 | 2026-01-30 | Warnings | PDC6A3C0OX |
| Optase | GLYCERIN | Scope Health Inc | 10c3e31d-779d-8ff6-e063-6294a90acd39 | 2026-01-30 | Warnings | PDC6A3C0OX |
| Optase | GLYCERIN | Scope Health Inc | 9e96976b-2990-79e0-e053-2995a90a0f29 | 2026-01-30 | Warnings | PDC6A3C0OX |
| Optase | GLYCERIN | Scope Health Inc | d81c1a4f-87b0-ee8c-e053-2995a90af9e5 | 2026-01-30 | Warnings | PDC6A3C0OX |
| Optase | GLYCERIN | Scope Health Inc | f452a2c4-c869-7bf5-e053-2995a90ac1a0 | 2026-01-30 | Warnings | PDC6A3C0OX |
| Regener-Eyes Ophthalmic Solution LITE XL | GLYCERIN OPHTHALMIC SOLUTION | M & M PRODUCTS, L.L.C. | 47ab9609-4291-30b2-e063-6394a90a421e | 2026-01-29 | Warnings | PDC6A3C0OX |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.